OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis $22.00 -0.01 (-0.02%) As of 08/9/2022 Add Compare Share Share Stock Analysis Stock Analysis About H. Lundbeck A/S Stock (OTCMKTS:HLUYY) Get H. Lundbeck A/S alerts:Sign Up Key Stats Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/AConsensus RatingN/A Company Overview H. Lundbeck A/S (OTCMKTS:HLUYY) is a Danish pharmaceutical company headquartered in Copenhagen that specializes in the research, development and commercialization of medicines for disorders of the central nervous system. Founded in 1915 by Hans Lundbeck, the company has built a long-standing focus on neuroscience, concentrating on therapies for psychiatric and neurological conditions rather than broader therapeutic areas. Lundbeck’s primary activities include discovery and clinical development of novel compounds, regulatory filings, manufacturing and global commercialization of prescription medicines aimed at brain health. Its therapeutic portfolio and development programs address conditions such as major depressive disorder, anxiety, schizophrenia, Alzheimer’s disease, Parkinson’s disease and other neurological disorders. Among its better-known products are selective serotonin reuptake inhibitors and later-generation antidepressants as well as treatments for cognitive symptoms of Alzheimer’s disease; the company also maintains an active pipeline of investigational medicines and lifecycle projects in neuroscience. Operating across Europe, the Americas and the Asia‑Pacific region, Lundbeck conducts research in-house and through collaborations with academic institutions and industry partners, and pursues licensing and commercial partnerships to extend the reach of its products. The company’s strategic emphasis remains on advancing treatments that improve outcomes for patients with brain disorders while reinforcing its research capabilities in neuroscience and neurodegenerative disease.AI Generated. May Contain Errors. Read More Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLUYY Stock News HeadlinesH. Lundbeck A/S (OTCMKTS:HLUYY) Share Price Crosses Below 50-Day Moving Average - What's Next?August 29, 2026 | americanbankingnews.comH LUNDBECK A/S AAugust 21, 2026 | finanznachrichten.deA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need. | Investors Alley (Ad)H LUNDBECK A/S BJuly 24, 2026 | finanznachrichten.deH. Lundbeck A/SEO-Medium-Term Nts 2025(25/29) BondJuly 7, 2026 | markets.businessinsider.comAvadel board declares Lundbeck proposal superior to Alkermes offerNovember 17, 2025 | msn.comAvadel Pharmaceuticals plc Confirms Receipt of Unsolicited Acquisition Proposal from H. Lundbeck A/SNovember 14, 2025 | quiverquant.comQLundbeck and Contera partner for oligonucleotide-based medicinesOctober 22, 2025 | msn.comSee More Headlines HLUYY Stock Analysis - Frequently Asked Questions How have HLUYY shares performed this year? H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) announced its earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to analysts' expectations of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%. Does H. Lundbeck A/S have any subsidiaries? H. Lundbeck A/S subsidiaries include these companies: Alder BioPharmaceuticals, and Prexton Therapeutics. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2015Today9/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:HLUYY CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Trailing Twelve Months)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:HLUYY) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.